Endospan Ltd., a company specializing in the endovascular repair of aortic arch disease, has secured $25.0 million in new funding from investors. Headquartered in Herzlia, Israel, Endospan is recognized for its NEXUS® Aortic Arch Stent Graft System, which is the only CE-approved off-the-shelf branched endovascular aortic arch system available. This innovative system is designed to address a wide range of aortic pathologies, including arch aneurysms, thoracic dissections, and penetrating aortic ulcers (PAU), by overcoming the specific anatomical challenges of the aortic arch.
The NEXUS® system represents a significant advancement for patients diagnosed with dilative lesions in or near the aortic arch. Historically, these patients have often faced open-chest surgery, a highly invasive procedure associated with considerable risks, lengthy hospitalizations, and prolonged recovery periods. Endospan’s minimally invasive solution offers a crucial alternative, providing stable and secured anatomical anchoring and atraumatic sealing through its "Dock and Lock" modular design, thereby improving patient outcomes and quality of life.
This latest funding round underscores investor confidence in Endospan’s pioneering technology and its potential to transform the treatment landscape for aortic arch disease. The $25.0 million in capital will be strategically deployed to accelerate the commercialization of the NEXUS® system across existing and new markets. It will also support ongoing research and development efforts aimed at further enhancing the system's capabilities and expanding its indications.
Endospan plans to leverage this investment to strengthen its market presence and continue its mission of providing less invasive, more effective treatment options for a greatly underserved patient population. The company is focused on advancing its technology and expanding access to the NEXUS® system globally, aiming to set new standards in endovascular aortic arch repair.
